What are the classifications of antihistamines and their typical clinical uses?

Antihistamine Classification

Antihistamines are classified into first-generation (sedating) and second-generation (non-sedating/less-sedating) agents, with second-generation antihistamines further subdivided based on brain H1 receptor occupancy into non-sedating (<20%), less-sedating (20-50%), and sedating (≥50%) categories 1.

Primary Classification System

First-Generation Antihistamines (Sedating)

These agents cross the blood-brain barrier extensively and cause significant central nervous system effects:

• Examples: Diphenhydramine, hydroxyzine, chlorpheniramine, clemastine, promethazine, brompheniramine, cyproheptadine 1
• Brain H1 receptor occupancy: ≥50% 2, 3
• Key adverse effects:
  • Sedation and drowsiness (often without subjective awareness)
  • Performance impairment in driving and work
  • Anticholinergic effects (dry mouth, urinary retention, constipation, narrow-angle glaucoma risk)
  • Increased fall risk and fractures in elderly 1

Critical pitfall: Performance impairment persists into the next day even when dosed only at bedtime due to prolonged half-lives and active metabolites 1. The AM/PM dosing strategy (second-generation in morning, first-generation at night) does NOT avoid daytime impairment and is not recommended 1.

Second-Generation Antihistamines

These have reduced CNS penetration but vary significantly in their sedative properties 1:

Non-Sedating (<20% H1 receptor occupancy)

• Fexofenadine: No sedation even at doses exceeding FDA recommendations 1
• Loratadine: No sedation at recommended doses 1
• Desloratadine: No sedation at recommended doses 1
• Bilastine: Classified as "non-brain-penetrating" with no psychomotor impairment even at double doses 3, 4

Less-Sedating (20-50% H1 receptor occupancy)

• Cetirizine: May cause mild drowsiness (13.7% vs 6.3% placebo) at standard 10mg dose, though typically without performance impairment 1
• Levocetirizine: Similar profile to cetirizine 1

Intranasal Antihistamines

• Azelastine: May cause sedation at recommended doses and has bitter taste 1
• Olopatadine: Minimal sedation reported 1

Clinical Application Algorithm

For allergic rhinitis treatment, follow this hierarchy 1:

1. First-line: Non-sedating second-generation oral antihistamines (fexofenadine, loratadine, desloratadine) or intranasal antihistamines

2. Avoid: First-generation antihistamines except when:

   • Anticholinergic effect specifically desired for persistent rhinorrhea unresponsive to other agents 1
   • Soporific effect needed at bedtime (with full patient counseling on next-day impairment risk) 1

3. Special populations requiring extra caution with first-generation agents 1:

   • Elderly (increased fall risk, cognitive impairment)
   • Patients with benign prostatic hypertrophy
   • Narrow-angle glaucoma
   • Cognitive impairment
   • Occupations requiring alertness (driving, operating machinery)

Important distinction: Among second-generation agents, loratadine and desloratadine may cause sedation at supratherapeutic doses, while fexofenadine maintains non-sedating properties even at higher doses 1. Cetirizine occupies an intermediate position with mild sedation possible at therapeutic doses 1.

Efficacy Considerations

No single second-generation antihistamine has proven superior efficacy for symptom control 1. The choice should prioritize safety profile, particularly sedation risk, over efficacy since therapeutic benefits are equivalent 1, 2, 4.

Intranasal antihistamines are equal or superior to oral second-generation antihistamines for seasonal allergic rhinitis and have clinically significant effects on nasal congestion 1, though they are generally less effective than intranasal corticosteroids 1.

The classification based on brain H1 receptor occupancy measured by PET scanning provides the most objective framework for predicting sedative risk and should guide clinical decision-making 2, 3, 4.